On Oct. 16, 2017, the Board of Directors for MassRoots (OTCQB:MSRT), a marijuana social media platform, ousted Isaac Dietrich as the company’s Chairman and Chief Executive Officer.
Despite strong opposition from former White House Press Secretary Sean Spicer and Attorney General Jeff Sessions, and the overall limitations imposed by federal illegality in the U.S., 2017 is shaping up to be a great year for the North American cannabis industry.
The stock of MedReleaf Corp. has recently outperformed those of other top marijuana stock players in Canada, and there could be further price gains going forward after the recently listed cannabis firm has found its footing and stopped the earlier quarterly revenue declines.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 6% in September on strong Canadian momentum.
Legal pot sales rose a stunning 34% in 2016 to $6.7 billion across North America, according to Arcview Market Research. But with growth this rapid, there’s bound to be more than a few marijuana stock investments that will be left behind.
Canada’s biggest medical cannabis producers are seeing their stock prices rise after the federal government announced a plan to levy a one dollar per gram tax on recreational marijuana sales.
Marijuana companies should be careful in overselling how much growth will be achieved or what the prospects will look like for the industry. There is a recent example that cannabis investors would be wise to review, and that’s what happened with Freshii Inc..
After the company announced it will tap investors for money to fuel R&D (research and development) and pre-commercialization efforts for its Dravet syndrome drug, shares in Zogenix (NASDAQ: ZGNX) are rallying 10% at 2 p.m. EDT today.
Toronto-based Trellis, which provides cannabis inventory management software, has raised $2.5 million led by Casa Verde Capital.
Marijuana stock investors are going to have to keep their eyes on the following two critical data points for each and every marijuana stock they’re considering buying, or that they already own.
New Brunswick recently announced how the province will manage the sale and distribution of marijuana. New Brunswick has also signed deals with Canopy Growth Corp. (TSX:WEED) and another company listed on the venture exchange.
The Ontario government announced September 8 that the LCBO will oversee the retail sale of cannabis in Ontario through standalone stores and an e-commerce site.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 11% in August.
Almost three months after the initial public offering (IPO) of MedReleaf Corp. (TSX:LEAF), shares have yet to do much in either direction. The company, which came to market in what was then described as a “botched IPO,” fell quickly out of the gate from its IPO price.
Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Undoubtedly, a reversal in the federal government’s laxness on pot would be terrible news for marijuana stock investors, but not every last company would be decimated. One marijuana stock could still thrive, even with Jeff Sessions waving the metaphorical sword at the pot industry: Scotts Miracle-Gro.
With prices for many major Canadian cannabis stocks such as Canopy Growth Corp., Aphria Inc., and Aurora Cannabis Inc. trading sideways over the past few months, investors are now wondering which direction stocks will move from here, and what the long-term play with this industry is overall.
Canopy Growth Corp. (TSX:WEED) was the first cannabis stock to the market and quickly captured the attention of traders and risk-taking growth investors alike. As a result, shares of Canopy skyrocketed 300% in a span of just a few months last year.
It seems as though news of recalls related to specific batches of bad marijuana from licensed Canadian producers has been coming in more frequently than marijuana investors and consumers would like to see.
The storied Silicon Valley venture firm Benchmark Capital has launched a slew of tech companies: Twitter, Uber, Snapchat, Instagram. Now its search for the next big thing has led it to … pot.
Whereas most weed businesses are working harder than ever to increase their grow capacity, Cronos Group is a company that’s trying to work smarter. Based in Canada, Cronos Group is an investment firm that primarily invests in Canadian-based pot companies involved in Canada’s medical-marijuana industry.
Any move by the Toronto Stock Exchange owner to stop settling trades for marijuana companies with U.S. operations would undermine the market’s regulatory system, according to one Canadian pot company.
There has been a lot of news in the marijuana industry this year. The medical marijuana industry exploded, and many new companies came to market in a frenzy, which reminded investors of the exciting technology bubble.
TMX Group Ltd. (TSX:X), the operator of the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV), has reportedly been speaking with regulators to figure out what will happen to Canadian marijuana producers with assets in the U.S.
GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
If you look around, chances are you won’t find many marijuana stocks struggling. But there’s always an outlier — and for the marijuana industry that’s drugmaker Insys Therapeutics.
TMX Group Ltd’s CEO on Thursday brushed off signs that the grip of Canada’s dominant stock exchange operator on overall trading volumes was slipping, saying recent market share losses were mostly due to its rejection of certain listings.
When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.
For many weed stocks, the summer of 2017 hasn’t been what you’d call a scorcher. However, three marijuana stocks have sizzled this summer.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 11% in July. This marks the first positive month for the North American Index since January.
If just a single clinical trial works in favor of Cara Therapeutics, it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
Identifying companies in great financial health is important when investing in an industry like marijuana. That being said, the Canadian marijuana stocks on our list all have current ratios of at least 10x, and debt to equity ratios under 20%.
In mid-June home lawn and fertilizer care specialist The Scotts Miracle-Gro Company (NYSE:SMG) lowered its full-year fiscal 2017 outlook, citing a more than 10% drop in mass retail sales compared to the year-to-date checkpoint from the previous year. That was caused by challenging weather this spring in core markets across the United States.
With excitement bubbling over the growth potential in the marijuana stock market, investors are keen on which pot stocks are the best to ride that wave of hype into comfortable returns.
The Creso Pharma Ltd (ASX: CPH) share price has been amongst the biggest movers on the market this morning. This morning the company revealed that it plans to expand into the Canadian market.
On July 27, 2017, Hightimes Holding Corp., the company behind High Times magazine, announced a merger agreement with Origo Acquisition Corporation (NASDAQ:OACQ), a special purpose acquisition company, as a means of making High Times a publicly traded company.
Over the trailing-12-month period through July 15, the average marijuana stock with a market cap in excess of $200 million — a dozen stocks in total, which excluded MedReleaf because it just went public a month ago — was up by 332%.
The Canadian government is moving quickly to legalize marijuana and, unlike the patchwork state-by-state approach unfolding in the U.S., Canada is set to make it legal nationwide by this time next year.
In total, four marijuana stocks jumped higher by at least 10% last week. Let’s take a brief look at some of these moves.
Few stocks have skyrocketed like Axim Biotechnologies. Last year, Axim ranked not only as the best marijuana stock in terms of overall performance, but also took the top spot among all biotech stocks.
Well, we have news for Canadian marijuana stock investors: There’s a new threat on the horizon, at least for our neighbors to the north.
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
Only 51 authorized licenses have been given to suppliers of medical marijuana in Canada. Canopy Growth Corporation holds four of them.
On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.
There have been two interesting developments with marijuana producers Aurora Cannabis Inc. (TSXV:ACB) and Aphria Inc. (TSX:APH).
Since Justin Trudeau’s election, the Canadian cannabis space has seen significant growth both in public and private sectors. The industry is gearing up for its entry into the legal recreational cannabis market set to open up by July 1, 2018.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 3% in June as continued losses in Canada closed out the Index’s second worst performing quarter since its inception in January 2015.
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
The results for Canopy Growth’s stock have been terrific so far, yielding a return of over 152% since inception. The stock has been performing well despite lacklustre results and frequent losses.